Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name IDH1 act mut
Gene Variant Detail

IDH1 act mut (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
IDH1 act mut chondrosarcoma sensitive Ivosidenib Guideline Actionable Tibsovo (ivosidenib) is included in guidelines as systemic therapy for patients with conventional or dedifferentiated chondrosarcoma harboring an IDH1 activating mutation (NCCN.org). detail...
IDH1 act mut intrahepatic cholangiocarcinoma predicted - sensitive Olutasidenib Phase Ib/II Actionable In a Phase I/II trial, Olutasidenib (FT-2102) treatment demonstrated acceptable safety and preliminary clinical activity in patients with IDH1-mutant intrahepatic cholangiocarcinoma, and led to stable disease in 23% (6/23) of 23 evaluable patients (J Clin Oncol 38, no. 5_suppl (May 28, 2020); NCT03684811). detail...
IDH1 act mut chondrosarcoma predicted - sensitive Olutasidenib Phase Ib/II Actionable In a Phase I/II trial, Olutasidenib (FT-2102) treatment demonstrated acceptable safety and preliminary clinical activity in patients with IDH1-mutant intrahepatic cholangiocarcinoma, and led to stable disease in 31% (4/13) of 13 evaluable patients (J Clin Oncol 38, no. 5_suppl (May 28, 2020); NCT03684811). detail...